Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model
Therapeutic efficacy of the novel matrix metalloproteinase (MMP) inhibitor Ro 28-2653 has been shown in various models of different tumor entities. We hypothesized that the inhibitor effect of Ro 28-2653 on the tumor growth could be improved by combination with chemotherapeutic drugs and examined th...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2007-02, Vol.59 (2), p.275-282 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 282 |
|---|---|
| container_issue | 2 |
| container_start_page | 275 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 59 |
| creator | ABRAMJUK, Claudia LEIN, Michael ROTHAUG, Winfried KRELL, Hans-Willi LOENING, Stefan A JUNG, Klaus |
| description | Therapeutic efficacy of the novel matrix metalloproteinase (MMP) inhibitor Ro 28-2653 has been shown in various models of different tumor entities. We hypothesized that the inhibitor effect of Ro 28-2653 on the tumor growth could be improved by combination with chemotherapeutic drugs and examined therefore the effect of Ro 28-2653 alone and in combination with etoposide or estramustine in the MatLyLu Dunning R-3327 rat tumor model characteristic for the androgen-independent prostate cancer (PCa).
In vitro effects were estimated measuring the proliferation of MatLyLu cells incubated with the three agents alone or in combination using the XTT test. The in vivo effects of the agents alone or in combination were examined by measuring the tumor weight 18 days after tumor cell injection.
The proliferation rate was only inhibited by etoposide while that effect was increased in combination with Ro 28-2653 and estramustine. Ro 28-2653 reduced the tumor weight by 86%. That effect was significantly increased in combination with etoposide to 92%.
The inhibitory effect of the MMP inhibitor Ro 28-2653 on the tumor growth in the Dunning PCa model is enhanced by the standard chemotherapeutic drug etoposide. A combined application of both agents could be considered as potential tool to improve the therapy of patients with advanced PCa after failure of hormonal treatment. |
| doi_str_mv | 10.1007/s00280-006-0269-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_213422849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1192435421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-2cb882d6fe457f8ed647f2a6aad4b253fcfc6378ec421342a10e82770ac686be3</originalsourceid><addsrcrecordid>eNpFkcuKFDEUhoMoTjv6AG4kCC5LTy6VpJcyjhcYEETXRSp1YmXoStokhc7r-WSm7IZeBZLv_08OHyEvGbxlAPpdAeAGOgDVAVf7Tj8iOyYF78BI8ZjsQEjZ9RrkFXlWyj0ASCbEU3LFlO4NM2ZH_t7G2UaHEw1xDmOoKT9Q9B5dpcnTOiNdbM3hD12w2sMhHXOqGKIteEnQb4ly03HVi3ZJXVrGRtSQIv0d6kyx1GyXtdQQkdo4UazpmEqYkDZkm9FaS7UVqbPZhZgWuxVtL9lW-mGNMcSfNOU6pxYNjtZ1aXOXNOHhOXni7aHgi_N5TX58vP1-87m7-_rpy837u86JXtWOu9EYPimPstfe4KSk9twqayc58l54550S2qCTnAnJLQM0XGuwThk1orgmr0-97bO_1rbTcJ_WHNvI4X-AG7lvEDtBrm1UMvrhmMNi88PAYNikDSdpQ5M2bNIG3TKvzsXruOB0SZwtNeDNGbDF2YPPzVgoF85I2DPBxD_PwqOL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213422849</pqid></control><display><type>article</type><title>Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>ABRAMJUK, Claudia ; LEIN, Michael ; ROTHAUG, Winfried ; KRELL, Hans-Willi ; LOENING, Stefan A ; JUNG, Klaus</creator><creatorcontrib>ABRAMJUK, Claudia ; LEIN, Michael ; ROTHAUG, Winfried ; KRELL, Hans-Willi ; LOENING, Stefan A ; JUNG, Klaus</creatorcontrib><description>Therapeutic efficacy of the novel matrix metalloproteinase (MMP) inhibitor Ro 28-2653 has been shown in various models of different tumor entities. We hypothesized that the inhibitor effect of Ro 28-2653 on the tumor growth could be improved by combination with chemotherapeutic drugs and examined therefore the effect of Ro 28-2653 alone and in combination with etoposide or estramustine in the MatLyLu Dunning R-3327 rat tumor model characteristic for the androgen-independent prostate cancer (PCa).
In vitro effects were estimated measuring the proliferation of MatLyLu cells incubated with the three agents alone or in combination using the XTT test. The in vivo effects of the agents alone or in combination were examined by measuring the tumor weight 18 days after tumor cell injection.
The proliferation rate was only inhibited by etoposide while that effect was increased in combination with Ro 28-2653 and estramustine. Ro 28-2653 reduced the tumor weight by 86%. That effect was significantly increased in combination with etoposide to 92%.
The inhibitory effect of the MMP inhibitor Ro 28-2653 on the tumor growth in the Dunning PCa model is enhanced by the standard chemotherapeutic drug etoposide. A combined application of both agents could be considered as potential tool to improve the therapy of patients with advanced PCa after failure of hormonal treatment.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-006-0269-7</identifier><identifier>PMID: 16758188</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject><![CDATA[Animals ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Body Weight - drug effects ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Disease Models, Animal ; Drug Resistance, Neoplasm ; Drug Screening Assays, Antitumor - methods ; Drug Synergism ; Estramustine - administration & dosage ; Etoposide - administration & dosage ; Gynecology. Andrology. Obstetrics ; Humans ; Injections, Intraperitoneal ; Male ; Male genital diseases ; Medical sciences ; Neoplasm Invasiveness - prevention & control ; Neoplasm Transplantation ; Nephrology. Urinary tract diseases ; Pharmacology. Drug treatments ; Piperazines - administration & dosage ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - pathology ; Pyrimidines - administration & dosage ; Rats ; Time Factors ; Tissue Inhibitor of Metalloproteinases - administration & dosage ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland]]></subject><ispartof>Cancer chemotherapy and pharmacology, 2007-02, Vol.59 (2), p.275-282</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-2cb882d6fe457f8ed647f2a6aad4b253fcfc6378ec421342a10e82770ac686be3</citedby><cites>FETCH-LOGICAL-c356t-2cb882d6fe457f8ed647f2a6aad4b253fcfc6378ec421342a10e82770ac686be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18409131$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16758188$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ABRAMJUK, Claudia</creatorcontrib><creatorcontrib>LEIN, Michael</creatorcontrib><creatorcontrib>ROTHAUG, Winfried</creatorcontrib><creatorcontrib>KRELL, Hans-Willi</creatorcontrib><creatorcontrib>LOENING, Stefan A</creatorcontrib><creatorcontrib>JUNG, Klaus</creatorcontrib><title>Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Therapeutic efficacy of the novel matrix metalloproteinase (MMP) inhibitor Ro 28-2653 has been shown in various models of different tumor entities. We hypothesized that the inhibitor effect of Ro 28-2653 on the tumor growth could be improved by combination with chemotherapeutic drugs and examined therefore the effect of Ro 28-2653 alone and in combination with etoposide or estramustine in the MatLyLu Dunning R-3327 rat tumor model characteristic for the androgen-independent prostate cancer (PCa).
In vitro effects were estimated measuring the proliferation of MatLyLu cells incubated with the three agents alone or in combination using the XTT test. The in vivo effects of the agents alone or in combination were examined by measuring the tumor weight 18 days after tumor cell injection.
The proliferation rate was only inhibited by etoposide while that effect was increased in combination with Ro 28-2653 and estramustine. Ro 28-2653 reduced the tumor weight by 86%. That effect was significantly increased in combination with etoposide to 92%.
The inhibitory effect of the MMP inhibitor Ro 28-2653 on the tumor growth in the Dunning PCa model is enhanced by the standard chemotherapeutic drug etoposide. A combined application of both agents could be considered as potential tool to improve the therapy of patients with advanced PCa after failure of hormonal treatment.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Body Weight - drug effects</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Disease Models, Animal</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug Screening Assays, Antitumor - methods</subject><subject>Drug Synergism</subject><subject>Estramustine - administration & dosage</subject><subject>Etoposide - administration & dosage</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Injections, Intraperitoneal</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Neoplasm Invasiveness - prevention & control</subject><subject>Neoplasm Transplantation</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - administration & dosage</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Pyrimidines - administration & dosage</subject><subject>Rats</subject><subject>Time Factors</subject><subject>Tissue Inhibitor of Metalloproteinases - administration & dosage</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpFkcuKFDEUhoMoTjv6AG4kCC5LTy6VpJcyjhcYEETXRSp1YmXoStokhc7r-WSm7IZeBZLv_08OHyEvGbxlAPpdAeAGOgDVAVf7Tj8iOyYF78BI8ZjsQEjZ9RrkFXlWyj0ASCbEU3LFlO4NM2ZH_t7G2UaHEw1xDmOoKT9Q9B5dpcnTOiNdbM3hD12w2sMhHXOqGKIteEnQb4ly03HVi3ZJXVrGRtSQIv0d6kyx1GyXtdQQkdo4UazpmEqYkDZkm9FaS7UVqbPZhZgWuxVtL9lW-mGNMcSfNOU6pxYNjtZ1aXOXNOHhOXni7aHgi_N5TX58vP1-87m7-_rpy837u86JXtWOu9EYPimPstfe4KSk9twqayc58l54550S2qCTnAnJLQM0XGuwThk1orgmr0-97bO_1rbTcJ_WHNvI4X-AG7lvEDtBrm1UMvrhmMNi88PAYNikDSdpQ5M2bNIG3TKvzsXruOB0SZwtNeDNGbDF2YPPzVgoF85I2DPBxD_PwqOL</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>ABRAMJUK, Claudia</creator><creator>LEIN, Michael</creator><creator>ROTHAUG, Winfried</creator><creator>KRELL, Hans-Willi</creator><creator>LOENING, Stefan A</creator><creator>JUNG, Klaus</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20070201</creationdate><title>Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model</title><author>ABRAMJUK, Claudia ; LEIN, Michael ; ROTHAUG, Winfried ; KRELL, Hans-Willi ; LOENING, Stefan A ; JUNG, Klaus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-2cb882d6fe457f8ed647f2a6aad4b253fcfc6378ec421342a10e82770ac686be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Body Weight - drug effects</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Disease Models, Animal</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug Screening Assays, Antitumor - methods</topic><topic>Drug Synergism</topic><topic>Estramustine - administration & dosage</topic><topic>Etoposide - administration & dosage</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Injections, Intraperitoneal</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Neoplasm Invasiveness - prevention & control</topic><topic>Neoplasm Transplantation</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - administration & dosage</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Pyrimidines - administration & dosage</topic><topic>Rats</topic><topic>Time Factors</topic><topic>Tissue Inhibitor of Metalloproteinases - administration & dosage</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ABRAMJUK, Claudia</creatorcontrib><creatorcontrib>LEIN, Michael</creatorcontrib><creatorcontrib>ROTHAUG, Winfried</creatorcontrib><creatorcontrib>KRELL, Hans-Willi</creatorcontrib><creatorcontrib>LOENING, Stefan A</creatorcontrib><creatorcontrib>JUNG, Klaus</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ABRAMJUK, Claudia</au><au>LEIN, Michael</au><au>ROTHAUG, Winfried</au><au>KRELL, Hans-Willi</au><au>LOENING, Stefan A</au><au>JUNG, Klaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>59</volume><issue>2</issue><spage>275</spage><epage>282</epage><pages>275-282</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Therapeutic efficacy of the novel matrix metalloproteinase (MMP) inhibitor Ro 28-2653 has been shown in various models of different tumor entities. We hypothesized that the inhibitor effect of Ro 28-2653 on the tumor growth could be improved by combination with chemotherapeutic drugs and examined therefore the effect of Ro 28-2653 alone and in combination with etoposide or estramustine in the MatLyLu Dunning R-3327 rat tumor model characteristic for the androgen-independent prostate cancer (PCa).
In vitro effects were estimated measuring the proliferation of MatLyLu cells incubated with the three agents alone or in combination using the XTT test. The in vivo effects of the agents alone or in combination were examined by measuring the tumor weight 18 days after tumor cell injection.
The proliferation rate was only inhibited by etoposide while that effect was increased in combination with Ro 28-2653 and estramustine. Ro 28-2653 reduced the tumor weight by 86%. That effect was significantly increased in combination with etoposide to 92%.
The inhibitory effect of the MMP inhibitor Ro 28-2653 on the tumor growth in the Dunning PCa model is enhanced by the standard chemotherapeutic drug etoposide. A combined application of both agents could be considered as potential tool to improve the therapy of patients with advanced PCa after failure of hormonal treatment.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>16758188</pmid><doi>10.1007/s00280-006-0269-7</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2007-02, Vol.59 (2), p.275-282 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_213422849 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Animals Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Body Weight - drug effects Cell Line, Tumor Cell Proliferation - drug effects Disease Models, Animal Drug Resistance, Neoplasm Drug Screening Assays, Antitumor - methods Drug Synergism Estramustine - administration & dosage Etoposide - administration & dosage Gynecology. Andrology. Obstetrics Humans Injections, Intraperitoneal Male Male genital diseases Medical sciences Neoplasm Invasiveness - prevention & control Neoplasm Transplantation Nephrology. Urinary tract diseases Pharmacology. Drug treatments Piperazines - administration & dosage Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Pyrimidines - administration & dosage Rats Time Factors Tissue Inhibitor of Metalloproteinases - administration & dosage Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T00%3A34%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20inhibitory%20effect%20of%20the%20matrix%20metalloproteinase%20inhibitor%20Ro%2028-2653%20in%20combination%20with%20estramustine%20and%20etoposide%20on%20the%20prostate%20carcinoma%20in%20the%20rat%20Dunning%20orthotopic%20tumor%20model&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=ABRAMJUK,%20Claudia&rft.date=2007-02-01&rft.volume=59&rft.issue=2&rft.spage=275&rft.epage=282&rft.pages=275-282&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-006-0269-7&rft_dat=%3Cproquest_cross%3E1192435421%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213422849&rft_id=info:pmid/16758188&rfr_iscdi=true |